The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially preterm babies and infants under six months old. The younger the child, the ...

With cold and flu season around the corner, Doctors recommend receiving the RSV vaccine ahead of the holidays.

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

In three months, the distribution of RSV vaccines will begin in the Americas, according to a PAHO announcement.

For adults aged 60 years or older, respiratory syncytial virus (RSV) vaccination is effective for preventing associat ...

Recent findings from a multi-state study reveal that the RSV vaccine is approximately 80% effective in preventing severe ...

This year, there are more options for those most susceptible to RSV, including a new vaccine and updated RSV vaccine guidance ...

RSV vaccines effective, but more people need to get them Date: October 28, 2024 Source: University of Rochester Medical Center Summary: Doctors detail what we learned after the first season ...

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...

More information: Angela R Branche, Real-world effectiveness studies of the benefit of RSV vaccines, The Lancet (2024).DOI: 10.1016/S0140-6736(24)02150-0 Amanda B Payne et al, Respiratory ...